Dalal Street Blogs provides information for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
CAUTION: Dalal Street Blogs publishes market news and educational content only. We do not promote, recommend or endorse any stock, and nothing here is a solicitation to buy or sell securities. Please consult a SEBI-registered adviser before investing.
Market News

Biocon Q2 Results (Nov 5, 2026): Profit Halves to ₹41 Crore on Delayed Shipments

Biocon Q2 results: a technician working at a pharmaceutical laboratory safety cabinet

Image by OsloMetX on Pixabay (Pixabay Content License)

By Dalal Street Blogs Editorial3 min read

Biocon Q2 results look ugly on the headline line, but the story underneath is mostly about timing. The Bengaluru drugmaker’s consolidated net profit fell 52% year on year to ₹41 crore in the September quarter of FY27, after shipments worth about $20 million missed the quarter-end cut-off while their costs were already booked, Business Standard reported on November 4.

The market didn’t panic. The numbers came out during trading hours and Biocon shares still ended 0.19% higher at ₹344 on the BSE.

In this article
  1. Biocon Q2 results: the numbers that matter
  2. Why one quarter got hit
  3. What management is betting on for the second half
  4. What it means for investors

Biocon Q2 results: the numbers that matter

  • Net profit: ₹41 crore, down from ₹85 crore a year earlier and ₹141 crore in the June quarter.
  • Revenue from operations: ₹4,389 crore, up 2% year on year.
  • EBITDA: ₹865 crore, down 7%, with the margin slipping to 20% from 22%.
  • Biopharma revenue: ₹3,583 crore, up 5%; within it, biosimilars grew 3% and generics 10%.
  • Services (mainly Syngene): down 9% year on year, but up 13% on a sequential basis.

Zoom out to the first half and the picture is far kinder. Biopharma revenue rose 11% and net profit climbed 57% to ₹182 crore for April to September.

Why one quarter got hit

Managing director Shreehas Tambe put it down to geopolitical disruptions delaying deliveries. The shipments, roughly 5% of biopharma revenue, reached customers only after September. Accounting rules meant the revenue couldn’t be recognised in Q2, but the related costs were. Tambe said the products were sold in October, so that revenue should show up in Q3, and called it a revenue recognition issue rather than a business problem.

That’s a plausible explanation, and we’ve seen this pattern before with exporters: a lumpy quarter that evens out over two. If you want a refresher on reading through such swings, our guide on how to analyse quarterly results of a company walks through comparing year-on-year and sequential numbers.

What management is betting on for the second half

Tambe said H2 would be stronger and pointed to four drivers. The ustekinumab biosimilar Yesintek holds a 34% share of the US market. The aflibercept biosimilar Yesafili is ramping up. Biocon has signed a 10-year pertuzumab supply deal in Brazil worth about $400 million, with supplies starting in Q4, and expects a European pertuzumab launch in the same quarter in a market it sizes at $600-700 million. And a second insulin fill-finish line in Malaysia is now running, adding capacity for US demand.

On margins, he said they should stay in the mid-20s range, though he gave no specific guidance for the second half. On semaglutide, the product has been tech-transferred to Brazilian partner Biomm, which is seeking approval from regulator Anvisa; Tambe said that could take 12 to 24 months.

What it means for investors

The thing to watch is simple. If Q3 revenue carries the roughly $20 million that slipped out of Q2, the profit dip will read as a one-off. If it doesn’t, the timing argument gets harder to defend. The services arm is worth tracking too, since Syngene’s sequential recovery fed into this quarter; we covered the stock separately in our Syngene shares update.

For company filings and price history, the BSE website is the primary source.

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.

Leave a Reply

Join the conversation

Commenting is open to registered readers. Sign up with just your email — no password needed, and it takes under a minute.

Sign up to comment Log in